For whom the bell tolls at Prima Biomed - CVac ovarian cancer vaccine

For whom the bell tolls at Prima Biomed

"Prima is developing a treatment for ovarian cancer and, at 22¢, its market capitalisation is $256 million. This is hefty for a company that is not forecast to make a profit for at least another four years (if it ever does)."

"The clinical results Prima Biomed has come up with so far do not seem to support its share price rise from 2¢ or so in early 2009, to peak at 39¢ this time last year. The full results of its preliminary (phase two) are due out in the next few months, but what we know so far is that the data from 21 patients ''has not demonstrated statistically significant results'', in the words of a report by Nomura Equity Research."

Read more: http://www.smh.com.au/business/for-whom-the-bell-tolls-at-prima-biomed-20120422-1xf1f.html#ixzz1sonQHSR0